Successful Treatment of U.S. Child With XDR Tuberculosis

This article originally appeared here.
Share this content:
Successful Treatment of U.S. Child With XDR Tuberculosis
Successful Treatment of U.S. Child With XDR Tuberculosis

MONDAY, Nov. 16, 2015 (HealthDay News) -- A 5-year-old child from the United States, diagnosed at age 2 with extensively drug-resistant (XDR) tuberculosis after traveling to India, is finally in remission, researchers report. A detailed account of the child's diagnosis and treatment, and the obstacles that clinicians at the Johns Hopkins Children's Center in Baltimore faced, was published in the December issue of The Lancet Infectious Diseases.

In this case, the child developed symptoms of fever and malaise after a three month visit to India. Although initial testing came back negative for tuberculosis, her medical team proceeded with empirical first-line tuberculosis treatment. Her condition improved at first, but a repeat X-ray revealed persistent lung inflammation. Repeat lab tests confirmed, after 12 weeks, that she harbored an extensively drug-resistant form of the disease.

The clinical team tried a new cocktail, combining five different drugs plus vitamin B6, and tracked progress by repeatedly administering low-dose computed tomography scans over six months. Symptom improvement was apparent weeks after the scans reflected declining lung inflammation and lower bacterial counts.

"Treatment has been successful so far, and the child is in remission," the authors write. "This report of XDR tuberculosis in a young child in the USA highlights the risks of acquiring drug-resistant tuberculosis overseas, and the unique challenges in management of tuberculosis in this susceptible population."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »